DK3299368T3 - Hidtil ukendte aminopyrimidinderivater - Google Patents
Hidtil ukendte aminopyrimidinderivater Download PDFInfo
- Publication number
- DK3299368T3 DK3299368T3 DK17191467.4T DK17191467T DK3299368T3 DK 3299368 T3 DK3299368 T3 DK 3299368T3 DK 17191467 T DK17191467 T DK 17191467T DK 3299368 T3 DK3299368 T3 DK 3299368T3
- Authority
- DK
- Denmark
- Prior art keywords
- hitherto unknown
- aminopyrimidine derivatives
- aminopyrimidine
- derivatives
- hitherto
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195081 | 2013-11-29 | ||
| EP14821285.5A EP3074386B1 (en) | 2013-11-29 | 2014-11-28 | Novel amino pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3299368T3 true DK3299368T3 (da) | 2020-05-25 |
Family
ID=49674216
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17191467.4T DK3299368T3 (da) | 2013-11-29 | 2014-11-28 | Hidtil ukendte aminopyrimidinderivater |
| DK14821285.5T DK3074386T3 (en) | 2013-11-29 | 2014-11-28 | Novel aminopyrimidine derivatives |
| DK20158961.1T DK3689865T3 (en) | 2013-11-29 | 2014-11-28 | Hidtil ukendte aminopyrimidinderivater |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14821285.5T DK3074386T3 (en) | 2013-11-29 | 2014-11-28 | Novel aminopyrimidine derivatives |
| DK20158961.1T DK3689865T3 (en) | 2013-11-29 | 2014-11-28 | Hidtil ukendte aminopyrimidinderivater |
Country Status (42)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| SI3888674T1 (sl) | 2014-04-07 | 2024-08-30 | Novartis Ag | Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19 |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
| SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| RU2020117196A (ru) | 2014-08-19 | 2020-10-15 | Новартис Аг | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей |
| JP6839074B2 (ja) | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CA2963935A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| EP3280795B1 (en) * | 2015-04-07 | 2021-03-24 | Novartis AG | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| IL303972A (en) | 2015-04-08 | 2023-08-01 | Novartis Ag | CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell |
| LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| US11413340B2 (en) | 2015-12-22 | 2022-08-16 | Novartis Ag | Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy |
| WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| CN116769050A (zh) | 2016-07-20 | 2023-09-19 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
| MY200337A (en) | 2016-10-07 | 2023-12-20 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain |
| JP7227131B2 (ja) | 2016-12-03 | 2023-02-21 | ジュノー セラピューティクス インコーポレイテッド | Ｃａｒ－ｔ細胞の投薬を決定するための方法 |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| WO2019006427A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| KR102845789B1 (ko) | 2017-11-01 | 2025-08-14 | 주노 쎄러퓨티크스 인코퍼레이티드 | B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드 |
| TWI694995B (zh) * | 2017-11-06 | 2020-06-01 | 美商美國禮來大藥廠 | Btk抑制劑化合物 |
| CN111989106A (zh) | 2017-12-01 | 2020-11-24 | 朱诺治疗学股份有限公司 | 基因工程化细胞的给药和调节方法 |
| CN108069911A (zh) * | 2017-12-14 | 2018-05-25 | 中国药科大学 | 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途 |
| WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| JP7438988B2 (ja) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | Ｂｃｍａキメラ抗原受容体及びその使用 |
| CN112424207B (zh) | 2018-07-25 | 2024-03-19 | 诺华股份有限公司 | Nlrp3炎性小体抑制剂 |
| EP3844149A1 (en) | 2018-08-29 | 2021-07-07 | Acerta Pharma B.V. | Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide |
| MX2021005024A (es) | 2018-11-01 | 2021-07-21 | Juno Therapeutics Inc | Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b. |
| CA3116413A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| SG11202105084VA (en) | 2018-11-16 | 2021-06-29 | Juno Therapeutics Inc | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| FI3886875T3 (fi) | 2018-11-30 | 2024-07-23 | Juno Therapeutics Inc | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä |
| CN113365660A (zh) | 2019-01-29 | 2021-09-07 | 朱诺治疗学股份有限公司 | 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| WO2020234780A1 (en) | 2019-05-23 | 2020-11-26 | Novartis Ag | Methods of treating asthma using a bruton's tyrosine kinase inhibitor |
| ES3039974T3 (en) * | 2019-05-23 | 2025-10-28 | Novartis Ag | A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria |
| EP3972603B1 (en) * | 2019-05-23 | 2024-09-04 | Novartis AG | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor |
| CN121471151A (zh) | 2019-05-23 | 2026-02-06 | 诺华股份有限公司 | Btk抑制剂的晶型 |
| JP7646671B2 (ja) * | 2019-12-23 | 2025-03-17 | バイオジェン・エムエイ・インコーポレイテッド | Ｂｔｋ阻害剤 |
| BR112022020333A2 (pt) | 2020-04-10 | 2022-11-22 | Juno Therapeutics Inc | Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b |
| CN116209444A (zh) * | 2020-08-14 | 2023-06-02 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物的晶型及其制备方法 |
| EP4196478A1 (en) | 2020-08-14 | 2023-06-21 | Novartis AG | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
| MX2023008671A (es) | 2021-01-26 | 2023-09-25 | Novartis Ag | Composicion farmaceutica. |
| US20240216330A1 (en) | 2021-04-02 | 2024-07-04 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| EP4395779A1 (en) | 2021-09-03 | 2024-07-10 | Novartis AG | Lou064 for treating multiple sclerosis |
| WO2023111802A1 (en) | 2021-12-14 | 2023-06-22 | Novartis Ag | Methods of treatment using lou064 |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
| US20250381272A1 (en) | 2022-06-22 | 2025-12-18 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| KR20250047766A (ko) | 2022-08-05 | 2025-04-04 | 주노 쎄러퓨티크스 인코퍼레이티드 | Gprc5d 및 bcma에 특이적인 키메라 항원 수용체 |
| WO2024069507A1 (en) | 2022-09-30 | 2024-04-04 | Novartis Ag | Synthesis methods and intermediates for the production of remibrutinib |
| CN120712102A (zh) | 2022-12-13 | 2025-09-26 | 朱诺治疗学股份有限公司 | 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途 |
| AU2024345255A1 (en) * | 2023-09-22 | 2026-03-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Heteroaryl compound, and preparation method therefor and use thereof in medicine |
| CN117024354B (zh) * | 2023-10-08 | 2023-12-08 | 天津凯莱英制药有限公司 | 瑞米布替尼的制备方法 |
| US20250243170A1 (en) | 2024-01-26 | 2025-07-31 | Novartis Ag | Remibrutinib drug substance and drug product substantially free of nitrosamine impurity |
| WO2025210469A2 (en) | 2024-04-02 | 2025-10-09 | Novartis Ag | Process of preparing remibrutinib substantially free of nitrosamine impurity |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
| GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| CA2426508A1 (en) | 2000-10-23 | 2002-05-16 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states |
| ES2332770T3 (es) | 2000-11-07 | 2010-02-12 | Novartis Ag | Derivados de indolilmaleimida como inhibidores de la proteina quinasa c. |
| AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
| PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
| EP2322203A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1578411A4 (en) | 2002-12-09 | 2007-05-02 | Univ Texas | PROCESS FOR THE SELECTIVE INHIBITION OF JANUS TYROSINE KINASE3 (JAK3) |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
| WO2005000833A1 (en) | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
| DK1704145T3 (da) | 2004-01-12 | 2012-09-24 | Ym Biosciences Australia Pty | Selektive kinaseinhibitorer |
| MX2007011041A (es) | 2005-03-10 | 2008-02-22 | Cgi Pharmaceuticals Inc | Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas. |
| EP2270200A3 (en) | 2006-09-11 | 2011-07-13 | CGI Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
| AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| US8232085B2 (en) | 2007-03-14 | 2012-07-31 | Bionsil S.R.L. | Isoform of bruton's tyrosine kinase (BTK) protein |
| US8426424B2 (en) | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| AU2009265813B2 (en) | 2008-07-02 | 2014-04-10 | F. Hoffmann-La Roche Ag | Novel phenylpyrazinones as kinase inhibitors |
| CN105362277A (zh) | 2008-07-16 | 2016-03-02 | 药品循环有限公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| US20100261776A1 (en) | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CA2748414A1 (en) | 2009-04-24 | 2010-10-28 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| BR112012021453A2 (pt) * | 2010-02-26 | 2017-02-21 | Boehringer Ingelheim Int | tienopirimidina, sua composição farmacêutica e seu uso |
| UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| WO2012135801A1 (en) | 2011-04-01 | 2012-10-04 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| PL2710007T3 (pl) | 2011-05-17 | 2020-06-01 | The Regents Of The University Of California | Inhibitory kinazy |
| LT2718270T (lt) | 2011-06-10 | 2022-08-10 | Merck Patent Gmbh | Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai |
| MX2014000130A (es) | 2011-06-28 | 2014-05-01 | Pharmacyclics Inc | Procedimientos y composiciones para la inhibicion de resorcion osea. |
| WO2013008095A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
| EP3778896A1 (en) | 2011-08-09 | 2021-02-17 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells |
| KR20250086805A (ko) | 2011-10-19 | 2025-06-13 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(btk)의 억제제의 용도 |
| CA2853498A1 (en) | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
| US8742098B2 (en) | 2011-12-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Inhibitors of Bruton's tyrosine kinase |
| US20150011751A1 (en) | 2012-03-09 | 2015-01-08 | Carna Biosciences, Inc. | Novel triazine derivative |
| JP6182593B2 (ja) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2013173518A1 (en) | 2012-05-16 | 2013-11-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| JP6348492B2 (ja) | 2012-08-10 | 2018-06-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物 |
| EP2903972B1 (en) | 2012-10-04 | 2019-12-04 | University of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
-
2014
- 2014-11-13 US US14/540,140 patent/US9512084B2/en active Active
- 2014-11-27 UY UY0001035858A patent/UY35858A/es active IP Right Grant
- 2014-11-27 AR ARP140104439A patent/AR098549A1/es active IP Right Grant
- 2014-11-27 JO JOP/2014/0341A patent/JO3314B1/ar active
- 2014-11-28 CN CN201910288376.XA patent/CN110172056B/zh active Active
- 2014-11-28 RS RS20230437A patent/RS64275B1/sr unknown
- 2014-11-28 EP EP20158961.1A patent/EP3689865B1/en active Active
- 2014-11-28 DK DK17191467.4T patent/DK3299368T3/da active
- 2014-11-28 PT PT201589611T patent/PT3689865T/pt unknown
- 2014-11-28 EP EP14821285.5A patent/EP3074386B1/en active Active
- 2014-11-28 RS RS20171206A patent/RS56657B1/sr unknown
- 2014-11-28 SI SI201432031T patent/SI3689865T1/sl unknown
- 2014-11-28 CA CA2926908A patent/CA2926908C/en active Active
- 2014-11-28 PL PL14821285T patent/PL3074386T3/pl unknown
- 2014-11-28 PL PL20158961.1T patent/PL3689865T3/pl unknown
- 2014-11-28 KR KR1020167013830A patent/KR102380539B1/ko active Active
- 2014-11-28 SI SI201430536T patent/SI3074386T1/en unknown
- 2014-11-28 AP AP2016009158A patent/AP2016009158A0/en unknown
- 2014-11-28 LT LTEP14821285.5T patent/LT3074386T/lt unknown
- 2014-11-28 ES ES17191467T patent/ES2791525T3/es active Active
- 2014-11-28 KR KR1020227009823A patent/KR102421388B1/ko active Active
- 2014-11-28 TN TN2016000128A patent/TN2016000128A1/en unknown
- 2014-11-28 FI FIEP20158961.1T patent/FI3689865T3/fi active
- 2014-11-28 PT PT148212855T patent/PT3074386T/pt unknown
- 2014-11-28 RS RS20200550A patent/RS60251B1/sr unknown
- 2014-11-28 EP EP17191467.4A patent/EP3299368B1/en active Active
- 2014-11-28 PT PT171914674T patent/PT3299368T/pt unknown
- 2014-11-28 HU HUE14821285A patent/HUE037588T2/hu unknown
- 2014-11-28 LT LTEP20158961.1T patent/LT3689865T/lt unknown
- 2014-11-28 CU CU2016000078A patent/CU24384B1/es unknown
- 2014-11-28 ES ES14821285.5T patent/ES2655527T3/es active Active
- 2014-11-28 TW TW103141506A patent/TWI652261B/zh active
- 2014-11-28 HU HUE17191467A patent/HUE049794T2/hu unknown
- 2014-11-28 EP EP25181626.0A patent/EP4606377A3/en active Pending
- 2014-11-28 EA EA201691125A patent/EA031218B1/ru not_active IP Right Cessation
- 2014-11-28 ES ES23161775T patent/ES3040769T3/es active Active
- 2014-11-28 JP JP2016535053A patent/JP6342495B2/ja active Active
- 2014-11-28 HR HRP20230585TT patent/HRP20230585T1/hr unknown
- 2014-11-28 SI SI201431570T patent/SI3299368T1/sl unknown
- 2014-11-28 MY MYPI2016701223A patent/MY179059A/en unknown
- 2014-11-28 MX MX2016006908A patent/MX367911B/es active IP Right Grant
- 2014-11-28 ES ES20158961T patent/ES2947770T3/es active Active
- 2014-11-28 WO PCT/IB2014/066422 patent/WO2015079417A1/en not_active Ceased
- 2014-11-28 DK DK14821285.5T patent/DK3074386T3/en active
- 2014-11-28 PL PL17191467T patent/PL3299368T3/pl unknown
- 2014-11-28 DK DK20158961.1T patent/DK3689865T3/da active
- 2014-11-28 NO NO14821285A patent/NO3074386T3/no unknown
- 2014-11-28 CN CN201480058515.5A patent/CN105683181B/zh active Active
- 2014-11-28 EP EP23161775.4A patent/EP4219478B1/en active Active
- 2014-11-28 HR HRP20171999TT patent/HRP20171999T1/hr unknown
- 2014-11-28 AU AU2014356069A patent/AU2014356069B2/en active Active
- 2014-11-28 PE PE2016000683A patent/PE20160869A1/es unknown
- 2014-11-28 LT LTEP17191467.4T patent/LT3299368T/lt unknown
- 2014-11-28 MY MYPI2020002915A patent/MY191381A/en unknown
- 2014-11-28 NZ NZ718835A patent/NZ718835A/en unknown
- 2014-11-28 UA UAA201603623A patent/UA117256C2/uk unknown
- 2014-11-28 HU HUE20158961A patent/HUE062248T2/hu unknown
- 2014-11-28 BR BR112016010397-1A patent/BR112016010397B1/pt active IP Right Grant
- 2014-11-28 MA MA39055A patent/MA39055B1/fr unknown
-
2016
- 2016-04-05 ZA ZA2016/02275A patent/ZA201602275B/en unknown
- 2016-04-06 IL IL244943A patent/IL244943B/en active IP Right Grant
- 2016-04-21 US US15/135,296 patent/US20160235746A1/en not_active Abandoned
- 2016-04-28 PH PH12016500791A patent/PH12016500791B1/en unknown
- 2016-05-03 CL CL2016001055A patent/CL2016001055A1/es unknown
- 2016-05-27 SV SV2016005206A patent/SV2016005206A/es unknown
- 2016-05-27 CR CR20160244A patent/CR20160244A/es unknown
- 2016-06-20 EC ECIEPI201654826A patent/ECSP16054826A/es unknown
-
2017
- 2017-12-22 CY CY20171101345T patent/CY1119705T1/el unknown
-
2018
- 2018-05-08 US US15/974,190 patent/US10457647B2/en active Active
- 2018-05-16 JP JP2018094772A patent/JP6667573B2/ja active Active
-
2019
- 2019-09-16 US US16/571,405 patent/US11180460B2/en active Active
-
2020
- 2020-05-12 HR HRP20200775TT patent/HRP20200775T1/hr unknown
- 2020-05-25 CY CY20201100478T patent/CY1122924T1/el unknown
-
2021
- 2021-10-22 US US17/508,054 patent/US11673868B2/en active Active
-
2023
- 2023-05-01 US US18/309,948 patent/US20230312483A1/en not_active Abandoned
- 2023-06-27 CY CY20231100301T patent/CY1126056T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3299368T3 (da) | Hidtil ukendte aminopyrimidinderivater | |
| BR112016008141A2 (pt) | Artigo | |
| HRP20180460T1 (hr) | Inhibitori syk | |
| DK3613453T3 (da) | Fordamper | |
| EP2990093A4 (en) | Dehumidifying device | |
| EP2979854A4 (en) | ITEMS | |
| DK3077047T3 (da) | Aramcholsalte | |
| DK3052081T3 (da) | Pastil | |
| DK3060460T3 (da) | Saddel | |
| DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
| DK2956698T3 (da) | Bindestrimler | |
| HUE037417T2 (hu) | Szubsztituált imidazopiridazinok | |
| PL2945641T3 (pl) | Cykloalkinowe pochodne sacharydów | |
| DK2952513T3 (da) | Azolbenzenderivat | |
| DK2946640T3 (da) | Langmuir-probe | |
| EP2943489A4 (en) | DEUTERATED MOMELOTINIB | |
| DE102013106534B8 (de) | Chromatographiepipettenspitze | |
| EP2991647A4 (en) | DEUTERED AMLEXANOX | |
| DK3087076T3 (da) | Imidazopyrazinonderivater | |
| EP2970310A4 (en) | 5-BROMO-indirubins | |
| EP2853297A4 (en) | kendama | |
| DK3071227T3 (da) | Fiskevaccine | |
| DE112014001252A5 (de) | Aufbissschiene | |
| EP3064843A4 (en) | Dehumidifier | |
| DK3086679T3 (da) | Sportssko |